Cipla Receives FDA’s ANDA Approval for its HFA Inhalation Aerosol to Treat Acute Episodes of Bronchospasm or to Prevent Asthmatic Symptoms
Cipla to Acquire Venus Remedies’ Elores to Strengthen its Critical Care Footprints in India
Shots:
- Cipla’s Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation is first device-based metered dose inhaler receives approval in the US which will further strengthen Cipla’s footprints in the US
- The first AB-rated generic version of Merck’s Proventil HFA Inhalation Aerosol is targeted to treat acute episodes of bronchospasm or prevention of asthmatic symptoms
- In end of Feb 2020, Proventil HFA Inhalation Aerosol had sales of $2.8B for 12-month period from Feb 2019. Additionally, the company is also planning to donate the product for meeting end to end ne
Click here to read full press release/ article | Ref: Cipla | Image: Cipla